Dalrada Corporation Appoints Harvey Hershkowitz as President of Dalrada Health

Rhea-AI Summary

Dalrada Corporation (OTCQB: DFCO) has appointed Harvey Hershkowitz as President of its subsidiary, Dalrada Health. With over 35 years in the healthcare sector, his experience is expected to bolster the company’s growth and expansion initiatives. Dalrada Health is involved in multiple segments, including GlanHealth™ and Pala Diagnostics, and has achieved significant milestones in healthcare services, including the launch of COVID-19 on-site testing. The global healthcare services market is projected to grow at a CAGR of 7% to $9,725.4 billion by 2023, positioning Dalrada favorably in this evolving landscape.

Positive

• Appointment of Harvey Hershkowitz is expected to enhance leadership and strategy execution in Dalrada Health.
• Dalrada Health has expanded its initiatives, including COVID-19 testing and clinical studies aimed at cervical cancer elimination.
• The global healthcare services market is projected to grow significantly, potentially benefiting Dalrada's growth.

Negative

• None.

SAN DIEGO--(BUSINESS WIRE)-- Dalrada Corporation (OTCQB: DFCO, "Dalrada") is announcing to its shareholders and the public that Harvey Hershkowitz, Director, was appointed as President of its subsidiary Dalrada Health. Mr. Hershkowitz's prominent career in the healthcare industry spans more than 35 years, during which he served as Chairman on many boards. This broad perspective provides Dalrada Health with a significant advantage in implementing its current initiatives and expanding its capabilities. Mr. Hershkowitz holds a remarkable track record for positioning corporations in the global market, where he actively expands his reach and network.

Brian Bonar, Chairman and CEO of Dalrada, states, "Given the growth and expansion of our healthcare division, we are bringing Harvey on as a seasoned executive to drive focus, execution, and results. His motivation for furthering the healthcare industry aligns with and empowers Dalrada's global vision and its business expansion implementation strategy."

Mr. Hershkowitz's experience includes guiding top Fortune 10 companies with consulting, Information Technology (IT), software, professional services, nursing schools, management, building and development. In addition, he has successfully spearheaded companies in business, IT, residential, wellness centers, commercial development, acute care hospitals, skilled nursing facilities, major physician groups, biosciences, pharmaceutical and healthcare construction boards.

“Dalrada continues to exceed expectations, and I am excited to help achieve our future goals. As a publicly-traded company with more than ten products & services, Dalrada serves the top growing industries, and we are looking forward to making our impact known,” said Mr. Hershkowitz.

Dalrada Health's business segments are GlanHealth™, cerVIA™, Empower Genomics, Pala Diagnostics, IHG, and Sòlas Rejuvenation + Wellness. Each has expanded its presence with notable achievements, including:

• Chief Medical Officer, Dr. Payal Keswarpu, shares cerVIA™ clinical study results at the 17th World Congress for Cervical Pathology and Colposcopy in support of the world's Cervical Cancer Elimination Initiative.
• Launch of COVID-19 on-site testing with Pala Diagnostics and Empower Genomics.
• Sòlas Rejuvenation + Wellness announces its flagship location with advanced medical-driven therapies and traditional wellness spa services.
• IHG (International Health Group) aids prominent regional healthcare provider with community outreach amid COVID-19.
• GlanHealth™ safer, non-toxic sanitizers facilitate the reopening of industries and businesses, including new topical product developments.

Trends in the healthcare industry reflect the growing acceptance and adoption of technology-driven informatics. Industry reports expect healthcare data analysis to create efficiencies that transform care facilities' operations and how practitioners engage with patients remotely.

“COVID-19 brought profound changes to the healthcare industry, and standard health care checkups and general health took a back seat. With these drastic shifts in the industry, we are committed to offering innovation with the right solutions to keep people healthy,” continued Hershkowitz.

According to industry data, the largest global healthcare services market region is North America, accounting for 40% of the market in 2019. From 2021, the global healthcare services market is expected to grow at a CAGR of 7% and reach $9725.4 billion in 2023. Alongside renewable "clean" energy and IT, healthcare is positioned as one of the three largest growing industries over the next 10 years.

Continuously building on its core life sciences, technology, and engineering practices, Dalrada operates under the tenet of bringing innovative products and services to a complex new world. As consumers, businesses, and governments seek alternative solutions, Dalrada's subsidiaries respond with affordable, available, accessible, and impactful innovations.

For more information on Dalrada and its subsidiaries, visit www.dalrada.com.

About Dalrada (DFCO)

With perseverance, valor, dedication, and vision, Dalrada Corporation is dedicated to tackling worldwide challenges of today and tomorrow.

Dalrada is a global company that operates under the tenet of creating impactful innovations that matter for the world. The Company works continually to produce disruptive solutions that bridge the gap of accessibility and accelerate positive change for current and future generations.

Established in 1982, the Company has since grown its footprint to include the business divisions: Dalrada Health, Dalrada Precision, and Dalrada Technologies. Each of Dalrada's subsidiaries actively produces affordable and accessible world-class solutions to global problems. For more information, please visit www.dalrada.com.

Disclaimer

Statements in this press release that are not historical facts, the statements are forward-looking, including statements regarding future revenues and sales projections, plans for future financing, the ability to meet operational milestones, marketing arrangements and plans, and shipments to and regulatory approvals in international markets. Such statements reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors and will be dependent upon a variety of factors including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our products and services in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211122005853/en/

Denise Mahaffey

858.283.1253

inquiries@dalrada.com

Source: Dalrada Corporation

FAQ

What recent leadership change occurred at Dalrada Corporation?

Harvey Hershkowitz was appointed as President of Dalrada Health.

How does Harvey Hershkowitz's experience benefit Dalrada Health?

His 35 years in healthcare and experience with top Fortune 10 companies provide valuable insights for the company's growth.

What are the key business segments of Dalrada Health?

Dalrada Health includes segments like GlanHealth™, cerVIA™, and Pala Diagnostics.

What is the forecast for the global healthcare services market?

The market is expected to grow at a CAGR of 7%, reaching $9,725.4 billion by 2023.